ESR1 and breast carcinoma: In ER + HER2- breast cancer, where tumorigenesis is driven by the estrogen-dependent pathway, anti-estrogen therapy is the cornerstone of treatment, and the prognosis is generally more favorable than that of other subtypes [26–28].